Bifogade filer
Press Release_ALK at EAACI 2026_final
Kalender
| Est. tid* | ||
| 2026-11-18 | 12:15 | Kvartalsrapport 2026-Q3 |
| 2026-08-20 | 12:15 | Kvartalsrapport 2026-Q2 |
| 2026-05-05 | - | Kvartalsrapport 2026-Q1 |
| 2026-03-17 | - | X-dag ordinarie utdelning ALK B 1.60 DKK |
| 2026-03-16 | - | Årsstämma |
| 2026-02-20 | - | Bokslutskommuniké 2025 |
| 2025-11-13 | - | Kvartalsrapport 2025-Q3 |
| 2025-08-21 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-06 | - | Kvartalsrapport 2025-Q1 |
| 2025-03-14 | - | X-dag ordinarie utdelning ALK B 0.00 DKK |
| 2025-03-13 | - | Årsstämma |
| 2025-02-19 | - | Bokslutskommuniké 2024 |
| 2024-11-14 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-23 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-03 | - | Kvartalsrapport 2024-Q1 |
| 2024-03-15 | - | X-dag ordinarie utdelning ALK B 0.00 DKK |
| 2024-03-14 | - | Årsstämma |
| 2024-02-08 | - | Bokslutskommuniké 2023 |
| 2023-11-15 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-09 | - | Kvartalsrapport 2023-Q1 |
| 2023-03-20 | - | X-dag ordinarie utdelning ALK B 0.00 DKK |
| 2023-02-03 | - | Bokslutskommuniké 2022 |
| 2022-11-10 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-11 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-12 | - | Kvartalsrapport 2022-Q1 |
| 2022-03-28 | - | Split ALK B 1:20 |
| 2022-03-17 | - | X-dag ordinarie utdelning ALK B 0.00 DKK |
| 2022-03-16 | - | Årsstämma |
| 2022-02-08 | - | Bokslutskommuniké 2021 |
| 2021-11-11 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-11 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-05 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-19 | - | X-dag ordinarie utdelning ALK B 0.00 DKK |
| 2021-03-18 | - | Årsstämma |
| 2021-02-10 | - | Bokslutskommuniké 2020 |
| 2020-11-11 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-12 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-06 | - | Kvartalsrapport 2020-Q1 |
| 2020-03-12 | - | X-dag ordinarie utdelning ALK B 0.00 DKK |
| 2020-03-11 | - | Årsstämma |
| 2020-02-05 | - | Bokslutskommuniké 2019 |
| 2019-11-07 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-13 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-09 | - | Kvartalsrapport 2019-Q1 |
| 2019-03-14 | - | X-dag ordinarie utdelning ALK B 0.00 DKK |
| 2019-03-13 | - | Årsstämma |
| 2019-02-07 | - | Bokslutskommuniké 2018 |
| 2018-11-09 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-15 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-04 | - | Kvartalsrapport 2018-Q1 |
| 2018-03-13 | - | X-dag ordinarie utdelning ALK B 0.00 DKK |
| 2018-03-12 | - | Årsstämma |
| 2018-02-06 | - | Bokslutskommuniké 2017 |
| 2017-11-10 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-16 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-09 | - | Kvartalsrapport 2017-Q1 |
| 2017-03-16 | - | X-dag ordinarie utdelning ALK B 5.00 DKK |
| 2017-03-15 | - | Årsstämma |
| 2017-02-07 | - | Bokslutskommuniké 2016 |
| 2016-11-10 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-16 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-04 | - | Kvartalsrapport 2016-Q1 |
| 2016-03-11 | - | X-dag ordinarie utdelning ALK B 5.00 DKK |
| 2016-03-10 | - | Årsstämma |
| 2016-02-09 | - | Bokslutskommuniké 2015 |
| 2015-11-12 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-18 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-05 | - | Kvartalsrapport 2015-Q1 |
| 2015-03-13 | - | X-dag ordinarie utdelning ALK B 5.00 DKK |
| 2015-03-12 | - | Årsstämma |
| 2015-02-09 | - | Bokslutskommuniké 2014 |
| 2014-11-14 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-13 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-08 | - | Kvartalsrapport 2014-Q1 |
| 2014-03-13 | - | X-dag ordinarie utdelning ALK B 5.00 DKK |
| 2014-03-12 | - | Årsstämma |
| 2014-02-05 | - | Bokslutskommuniké 2013 |
| 2013-11-08 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-14 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-03 | - | Kvartalsrapport 2013-Q1 |
| 2013-03-13 | - | X-dag ordinarie utdelning ALK B 5.00 DKK |
| 2013-03-12 | - | Årsstämma |
| 2013-02-05 | - | Bokslutskommuniké 2012 |
| 2012-11-12 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-16 | - | Kvartalsrapport 2012-Q2 |
| 2012-05-10 | - | Kvartalsrapport 2012-Q1 |
| 2012-03-28 | - | X-dag ordinarie utdelning ALK B 5.00 DKK |
| 2012-03-27 | - | Årsstämma |
| 2012-02-22 | - | Bokslutskommuniké 2011 |
| 2011-11-11 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-16 | - | Kvartalsrapport 2011-Q2 |
| 2011-05-10 | - | Kvartalsrapport 2011-Q1 |
| 2011-04-04 | - | X-dag ordinarie utdelning ALK B 5.00 DKK |
| 2011-04-01 | - | Årsstämma |
| 2010-03-29 | - | X-dag ordinarie utdelning ALK B 5.00 DKK |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Large Cap Copenhagen |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which will this year take part in Istanbul, Türkiye from 12 to 15 June 2026, the Danish pharmaceutical company ALK will present data and key insights within anaphylaxis, food and respiratory allergy.
At two ALK symposia, FlashTalk, oral and poster sessions at the EAACI 2026 scientific programme, ALK will present data on real-world use and clinical implementation of nasal adrenaline in anaphylaxis and share key learnings from 20 years of experience with SLIT tablets.
The two symposia will take place as follows:
Friday 12 June, 12:00-13:00:
From evidence to practice: Real-world use and clinical implementation of nasal adrenaline in anaphylaxis.
The symposium will address the unmet needs in paediatric and adult anaphylaxis management, the role of nasal adrenaline, including a presentation of real-world use, patient preference and clinical implementation.
Saturday 13 June, 12:00-13:00:
20 years of SQ SLIT-tablet experience: Key learnings and new horizons
The symposium will address the disease modifying and preventative benefits of allergy immunotherapy, the clinical benefits beyond allergic rhinitis and share efficacy and safety outcomes of a peanut SLIT-tablet phase I/II trial.
Simon Lawton, Global Medical Affairs, Chief medical Office at ALK says:
“We are looking forward to contributing to this year’s EAACI congress where we will showcase the important innovation under way at ALK across anaphylaxis and food allergy. We will also share key insights grounded in robust science and 20 years’ experience with SLIT-tablets. We hope that many EAACI attendees will join our symposia.”
In total, ALK has contributed to 29 abstracts in the scientific programme. Of particular note are additional efficacy and safety findings from clinical trials in adults and children with allergic rhinitis/rhino conjunctivitis treated with SLIT-tablets.
Key highlights of ALK’s contribution include:
| Therapy area | Abstract title | Lead author | Abstract Number/ Presentation Details |
| Anaphylaxis | Patient Preferences for Nasal Adrenaline Spray versus Adrenaline Auto-Injectors in Anaphylaxis: A Multi-Country Discrete Choice Experiment | Worm M | #001368 Thematic poster session Sunday 14 June 2026, 12:15-13:15 |
| Anaphylaxis | Healthcare Professionals’ Perspectives on Anaphylaxis Management: A Multi-Country Survey comparing Adrenaline Auto-Injectors and Nasal Adrenaline Sprays | Fox A | #001283 Flash talks session Saturday 13 June 2026, 16:45-18:15 |
| Anaphylaxis | Intranasal Adrenaline Associated with Lower Administration-Related Anxiety and Higher Willingness to Use Versus Adrenaline Auto-Injectors | Mack D | #000889 Flash talks session Saturday 13 June 2026, 16:45-18:15 |
| Anaphylaxis | Comparative Ease-of-Use Assessment of a Nasal Adrenaline Spray with an Adrenaline Auto-Injector in Children, Adults and Caregivers | Mack D | #000890 Flash talks session Saturday 13 June 2026, 16:45-18:15 |
| Respiratory allergy | Effect of SQ SLIT-tablets on asthma symptoms and safety in children with allergic rhinitis and with or without concomitant asthma across multiple trials | Pfaar O | #000781 Oral presentation Sunday 14 June 2026, 08:45 - 10:15 |
| Respiratory allergy | Symptom control and reduced intranasal corticosteroid use in children with allergic rhinitis/rhinoconjunctivitis treated with SQ house dust mite SLIT-tablet: A responder analysis | Pfaar O | #000815 Flash talks session Sunday 14 June 2026, 12:15-13:15 |
| Respiratory allergy | Reduction in symptom and medication scores in the first week of the first pollen season in children and adults treated with SQ SLIT-tablets across phase III trials | Durham S | #100185 Flash talks session Sunday 14th June 2026, 12:15 – 13:15 |
| Real-world evidence | Long-term real-world effectiveness of allergen immunotherapy on respiratory infections in children and adults with allergic rhinitis and asthma | Woehlk C | #000748 Flash talks session Friday 12 June 2026, 12:00-13:00 |
| Real-world evidence | Effectiveness of sublingual immunotherapy (SLIT) tablets on dispensed asthma medications and treatment regimens: Results from the Real-world Evidence of aLlergy immunotherapY (RELY) study | Woehlk C | #000751 Oral presentation Saturday 13 June 2026, 13:15-14:45 |
| Real-world evidence | Long-term effectiveness of HDM SLIT-tablets on symptom-relieving prescriptions: Results from the Japanese register-based study, Real-world Evidence of house dust Mite sublingual Immunotherapy Tablets (REMIT) | Durham S | #001258 Oral presentation Saturday 13 June 2026, 13:15-14:45 |
For further information, please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Maiken Riise Andersen, tel. +45 5054 1434
About ALK
ALK is a global specialty pharmaceutical company focused on allergy. ALK's activities cover the entire value chain of developing, sourcing, producing, and marketing a diversified portfolio of products for diagnosing and treating respiratory allergies and severe allergic reactions (anaphylaxis) in both children and adults. Headquartered in Denmark, ALK employs around 2,700 people worldwide and is listed on Nasdaq Copenhagen (Nasdaq: ALK B). Visit us at www.alk.net.